» Articles » PMID: 21494915

Overexpression of P18INK⁴C in LLC-PK1 Cells Increases Resistance to Cisplatin-induced Apoptosis

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2011 Apr 16
PMID 21494915
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Studies have demonstrated that cyclin-dependent kinase inhibitors (CDKI) that inhibit cell-cycle progression have a protective effect against acute kidney injury (AKI). Most studies have focused on the CIP/KIP family members of CDKI; only a few have explored the role of INK4 family members in AKI. Because INK4 family members block the G1-S transition, we postulated that they should have protective effects against AKI. The most conserved INK4 member is p18, so we selected it to explore its effects on cisplatin-induced renal cell injury. We overexpressed p18 in renal tubular epithelial cells (LLC-PK1) by transient transfection and investigated its effects on the cell cycle and proliferation. After transfection, cell injury was induced by cisplatin (100 μM) incubation for 24 h in a standard medium. The effect of p18 was assayed by assessing cell necrosis and apoptosis in transfected cells. The endoplasmic reticulum stress (ERS) pathway was evaluated to interpret the possible mechanism of p18 action in cisplatin-induced renal cell injury. Overexpression of p18 arrested cell cycle progression in the G1 phase and inhibited proliferation. Compared with vehicle transfection, p18 overexpression did not affect cisplatin-induced necrosis, but it reduced the percentage of apoptotic cells significantly. The severity of ERS induced by cisplatin was also decreased by p18 overexpression. P18 protects against cisplatin-induced renal cell injury. The mechanism of p18 protection may lie in its effect on the cell death pathway.

Citing Articles

The distinct effects of P18 overexpression on different stages of hematopoiesis involve TGF-β and NF-κB signaling.

Yi D, Zhu L, Liu Y, Zeng J, Chang J, Sun W Sci Rep. 2021; 11(1):24014.

PMID: 34907231 PMC: 8671498. DOI: 10.1038/s41598-021-03263-2.


Heme Oxygenase 1 as a Therapeutic Target in Acute Kidney Injury.

Bolisetty S, Zarjou A, Agarwal A Am J Kidney Dis. 2017; 69(4):531-545.

PMID: 28139396 PMC: 5366088. DOI: 10.1053/j.ajkd.2016.10.037.


Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.

Saba N, Wilson M, Doho G, DaSilva J, Isett R, Newman S Head Neck Pathol. 2014; 9(2):223-35.

PMID: 25236499 PMC: 4424213. DOI: 10.1007/s12105-014-0566-0.


Cell cycle-related genes p57kip2, Cdk5 and Spin in the pathogenesis of neural tube defects.

Li X, Yang Z, Zeng Y, Xu H, Li H, Han Y Neural Regen Res. 2014; 8(20):1863-71.

PMID: 25206495 PMC: 4145975. DOI: 10.3969/j.issn.1673-5374.2013.20.005.

References
1.
Devarajan P . Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006; 17(6):1503-20. DOI: 10.1681/ASN.2006010017. View

2.
Peter M, Herskowitz I . Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 1994; 79(2):181-4. DOI: 10.1016/0092-8674(94)90186-4. View

3.
Price P, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein R . Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol. 2006; 17(9):2434-42. PMC: 1698291. DOI: 10.1681/ASN.2006020162. View

4.
Hirai H, Roussel M, Kato J, Ashmun R, Sherr C . Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995; 15(5):2672-81. PMC: 230497. DOI: 10.1128/MCB.15.5.2672. View

5.
MORGAN D . Principles of CDK regulation. Nature. 1995; 374(6518):131-4. DOI: 10.1038/374131a0. View